March 18 (Reuters) - Consumer healthcare giant Haleon ( HLN )

said on Monday that Pfizer ( PFE ) will sell about 630

million of its shares in the company, reducing the US

drugmaker's stake to about 24%.

Pfizer ( PFE ), which currently holds a 32% stake in Haleon ( HLN ), said

last May it planned to cut its ownership in a "slow and

methodical" manner within months.

The offer price per share is expected to be announced on or

around March 19, following the completion of a book-building

process, Haleon ( HLN ) said in a statement.

Haleon ( HLN ), which makes household brands such as Sensodyne

toothpaste and Advil painkillers, was spun out of British

drugmaker GSK in July 2022.

Since then, GSK has sold down its stake in the company, with

the last sale in January bringing down its shareholding to 4.2%.